A data analysis from a randomized clinical trial for stage 3 colon cancer patients by investigators at Dana-Farber Brigham Cancer Center found that patients with evidence of residual cancer in their blood after surgery to remove the cancer, may benefit from adding of celecoxib, to post surgery treatment.
Cardurion touts Phase 2 data for PDE9 inhibitor in heart failure, plans for two more trials
Cardurion Pharmaceuticals touted positive data for its heart failure drug and announced plans to pursue two more trials, three years after the Massachusetts biotech scored